Helin-Salmivaara Arja, Huupponen Risto, Virtanen Arja, Lammela Jari, Klaukka Timo
Centre for Pharmacotherapy Development, Box 55, FIN, 00301, Helsinki, Finland.
Eur J Clin Pharmacol. 2005 Jul;61(5-6):425-31. doi: 10.1007/s00228-005-0949-y. Epub 2005 Jun 11.
A number of drugs used concurrently with non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of gastrointestinal (GI) haemorrhage. We studied the prescribing of NSAIDs with corticosteroids, oral anticoagulants or selective serotonin re-uptake inhibitors (SSRIs), as well as the use of gastroprotection among continuous and non-continuous users of NSAIDs in Finland.
Concurrent use of various drugs was analysed in a nested case-control study in a population-based cohort of NSAID users in 2000 using data in the National Prescription Database.
Prescribing of any other drug with the potential to increase the risk of GI bleeding with NSAIDs was five times [5.2; 95% confidence interval (CI) 4.7-5.9] more common among continuous than non-continuous NSAID users, and the odds ratio for oral corticosteroids was 8.0 (95% CI 6.6-9.6). Of patients using continuous NSAIDs with oral corticosteroids, 73.3% had rheumatoid arthritis (RA). After excluding RA patients, the odds ratio remained high (4.5; 95% CI 3.3-6.1) and at the same level as for SSRIs (3.7; 3.1-4.4). Gastroprotective drugs were prescribed for 6.8% of the continuous users of NSAIDs alone, and for 20.4% of patients taking any of the studied drug combinations with NSAIDs. The continuous users of NSAIDs alone had gastroprotection 2.9 (2.5-3.3) times more often than other users of NSAIDs. With drug combinations (NSAID+corticosteroid, NSAID+SSRI, NSAID+anticoagulants), the use of gastroprotection did not differ from patients using lower amounts of NSAIDs.
When prescribing NSAIDs, situations leading to habitual use should be avoided, potential complications due to clustering of risk factors recognised, and gastroprotection prescribed for patients with increased risk of GI haemorrhage.
多种与非甾体抗炎药(NSAIDs)同时使用的药物会增加胃肠道(GI)出血风险。我们研究了芬兰NSAIDs与皮质类固醇、口服抗凝剂或选择性5-羟色胺再摄取抑制剂(SSRIs)的联合使用情况,以及NSAIDs连续使用者和非连续使用者的胃保护药物使用情况。
2000年,利用国家处方数据库中的数据,在一项基于人群的NSAIDs使用者队列的巢式病例对照研究中分析了各种药物的联合使用情况。
连续使用NSAIDs的患者中,同时开具任何其他有可能增加NSAIDs致GI出血风险药物的情况比非连续使用者普遍5倍[5.2;95%置信区间(CI)4.7 - 5.9],口服皮质类固醇的比值比为8.0(95%CI 6.6 - 9.6)。在连续使用NSAIDs并同时使用口服皮质类固醇的患者中,73.3%患有类风湿性关节炎(RA)。排除RA患者后,比值比仍很高(4.5;95%CI 3.3 - 6.1),与SSRIs的比值比水平相同(3.7;3.1 - 4.4)。仅单独连续使用NSAIDs的患者中,6.8%开具了胃保护药物,而在使用任何一种所研究的与NSAIDs联合用药的患者中,这一比例为20.4%。仅单独连续使用NSAIDs的患者接受胃保护的频率比其他NSAIDs使用者高2.9(2.5 - 3.3)倍。对于联合用药(NSAID + 皮质类固醇、NSAID + SSRI、NSAID + 抗凝剂),胃保护药物的使用情况与使用较少剂量NSAIDs的患者没有差异。
开具NSAIDs处方时,应避免导致习惯性使用的情况,识别危险因素聚集导致的潜在并发症,并为GI出血风险增加的患者开具胃保护药物。